{
    "clinical_study": {
        "@rank": "41704", 
        "arm_group": {
            "arm_group_label": "DD-25", 
            "arm_group_type": "Experimental", 
            "description": "A concentration of 0.025% of topical DD-25 cream."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the efficacy of DD-25, a new topical drug, on\n      plaque Psoriasis Vulgaris.\n\n      The study will include subjects at plaque stage from 5-20% body area involvement. A total of\n      30 subjects will be treated with cream application on affected areas twice daily for three\n      weeks.The efficacy of the preparation will be documented by PASI score, Global physician\n      assessment and photos."
        }, 
        "brief_title": "Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris : Proof of Concept Study", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Psoriasis Vulgaris", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "detailed_description": {
            "textblock": "Psoriasis Vulgaris remains a widespread clinical entity with chronic outflares and various\n      regimens of treatment, none of them definitive. A new safe and efficacious, external\n      treatment is required for."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject age 18-60\n\n          2. Diagnosis of PS by a dermatologist with lesions on arms, legs or trunk\n\n          3. Subjects have stable plaque PS, mild to moderate form, Body Surface Area of 5-20%.\n\n          4. Subject understood and signed an informed consent form\n\n        Exclusion Criteria:\n\n          1. Guttate, erythrodermic, palm-plantar or pustular psoriasis as sole or predominant\n             form of psoriasis.\n\n          2. Hypersensitivity to sunlight; history of Lupus, PMLE, or any disease known to be\n             worsened by UV light exposure\n\n          3. Pregnancy, breast feeding\n\n          4. History of cancer, excluding non-melanoma skin cancer.\n\n          5. Patients with history of ischemic heart disease (e.g. angina pectoris, myocardial\n             infarction); cerebrovascular syndromes, peripheral vascular or uncontrolled\n             hypertension. Subjects with known severe hepatic and/or severe renal insufficiency.\n\n          6. Any medical condition that, in the opinion of the Investigator, would jeopardize the\n             health of the patient during the course of this study.\n\n          7. Systemic treatment with biological therapies with a possible effect on psoriasis\n             vulgaris within 4 months or 5 drug half-lives prior to checkup.\n\n          8. Systemic treatments with all other therapies than biologicals, with a potential\n             effect on psoriasis vulgaris (e.g., corticosteroids, vitamin D analogues, retinoids,\n             immuno-suppressants) within the 8-week period prior to randomization. Subjects using\n             within the 8 week period prior to randomization PUVA or Phototherapy. Use of SSRI or\n             MAO inhibitors.\n\n          9. Subjects using one of the following TOPICAL drugs for the treatment of PS within 2\n             weeks prior to randomization: e.g. WHO group I-II corticosteroids, retinoids, Vit. D\n             analogues, immunomodulators, Anthracene derivatives, Salicylic acid.\n\n         10. Subjects with current participation in any other interventional clinical or subjects\n             with any concomitant dermatological disorder(s) which might preclude accurate\n             evaluation of the psoriasis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01702324", 
            "org_study_id": "DD-25", 
            "secondary_id": "0290-12-TLV"
        }, 
        "intervention": {
            "arm_group_label": "DD-25", 
            "description": "A topical DD-25 cream at 0.025% concentration.", 
            "intervention_name": "DD-25", 
            "intervention_type": "Drug", 
            "other_name": "Fortuderm DD-25 Psoriasis Cream"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Psoriasis Vulgaris", 
            "Plaque", 
            "Topical", 
            "Treatment"
        ], 
        "lastchanged_date": "October 4, 2012", 
        "location": {
            "contact": {
                "email": "dvoray@tasmc.health.gov.il", 
                "last_name": "Dvora Krulfeld, M.A.", 
                "phone": "97236973768"
            }, 
            "facility": {
                "address": {
                    "city": "Tel Aviv", 
                    "country": "Israel", 
                    "zip": "64239"
                }, 
                "name": "Tel Aviv Sourasky Medical Center"
            }, 
            "investigator": {
                "last_name": "Hagit Matz, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris : Proof of Concept Study", 
        "overall_contact": {
            "email": "dasc01@yahoo.com", 
            "last_name": "Avi Dascalu, M.D., Ph.D.", 
            "phone": "972-3-6099005"
        }, 
        "overall_official": {
            "affiliation": "Dept of Dermatology, Tel Aviv Sourasky Medical Center", 
            "last_name": "Hagit Matz, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ethics Commission", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluation of the effectiveness of DD-25 over a period of 3 weeks treatment by analyzing the changes in the Psoriasis Area & Severity Index (PASI) in moderate to mild Plaque Psoriasis patients. Improvement to be assessed by changes in erythema, induration and desquamation as seen on days 0, 10 and 21.", 
            "measure": "Efficacy after 3 weeks as compared to baseline.", 
            "safety_issue": "No", 
            "time_frame": "3 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01702324"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "PASI reduction of 50%", 
            "safety_issue": "No", 
            "time_frame": "3 weeks"
        }, 
        "source": "Fortuderm Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fortuderm Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}